SPHK1 and autosomal dominant polycystic kidney disease: Additionally, we identified putative therapeutic classes not previously associated to ADPKD such as DNA Topoisomerase and Sphingosine Kinase (SphK) inhibitors, of which the first class also reduced in vitro cyst growth.